Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data.
A Irodi,Tzyvia Rye,K Herbert,K Herbert,Michael Churchman,Clare Bartos,Melanie Mackean,Fiona Nussey,CS Herrington,Charlie Gourley,Robert L Hollis +10 more
56
TL;DR: The clinical landscape of ovarian carcinoma (OC) over time is investigated to find out whether changes in prognosis over time are driven by disease progression or by underlying medical conditions.
read more
About: This article is published in British Journal of Obstetrics and Gynaecology. The article was published on 13 Apr 2020. and is currently open access. The article focuses on the topics: Debulking & Population.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Clear cell carcinoma of the ovary: a clinical and molecular perspective.
TL;DR: Gene expression profiling shows upregulation of hepatocyte nuclear factor 1-beta and oxidative stress-related genes, and has identified epithelial-like and mesenchymal-like tumor subgroups, and the benefit of platinum-based chemotherapy remains the mainstay of first-line therapy.
Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome.
Robert L Hollis,John P. Thomson,Barbara Stanley,Michael Churchman,Alison M. Meynert,Tzyvia Rye,Clare Bartos,Yasushi Iida,Yasushi Iida,Ian Croy,Melanie Mackean,Fiona Nussey,Aikou Okamoto,Colin A. Semple,Charlie Gourley,C. Simon Herrington +15 more
TL;DR: Endometrioid ovarian carcinoma (EnOC) demonstrates substantial clinical and molecular heterogeneity, and the WNT, MAPK/RAS and PI3K pathways are identified as good candidate targets for molecular therapeutics in EnOC.
Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
TL;DR: Lheureux et al. as discussed by the authors identified molecular subclasses of clear cell ovarian carcinoma (CCOC) and assessed their impact on clinical presentation and outcomes using a targeted deep sequencing panel of 163 putative CCOC driver genes.
53
Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome
Robert L Hollis,John P. Thomson,Barbara Stanley,Michael Churchman,Alison M. Meynert,Tzyvia Rye,Clare Bartos,Yasushi Iida,Yasushi Iida,Ian Croy,Melanie Mackean,Fiona Nussey,Aikou Okamoto,Colin A. Semple,Charlie Gourley,C. Simon Herrington +15 more
TL;DR: The largest genomic study of EnOCs to date is reported, performing whole exome sequencing of 112 cases following rigorous pathological assessment and identifying the WNT, MAPK/RAS and PI3K pathways as good candidate targets for molecular therapeutics in EnOC.
Molecular characteristics and clinical behaviour of epithelial ovarian cancers.
TL;DR: Ovarian carcinoma (OC) is an umbrella term for multiple distinct diseases (histotypes), each with their own developmental origins, clinical behaviour and molecular profile as mentioned in this paper , and management is progressing away from a one-size-fits-all approach, toward more molecularly-driven, histotype-specific management strategies.
46
References
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray,Jacques Ferlay,Isabelle Soerjomataram,Rebecca L. Siegel,Lindsey A. Torre,Ahmedin Jemal +5 more
TL;DR: A status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.
80.7K
Cancer statistics, 2018
TL;DR: The combined cancer death rate dropped continuously from 1991 to 2015 by a total of 26%, translating to approximately 2,378,600 fewer cancer deaths than would have been expected if death rates had remained at their peak.
16.6K
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore,Nicoletta Colombo,Giovanni Scambia,Byoung Gie Kim,Ana Oaknin,Michael Friedlander,Alla Lisyanskaya,Anne Floquet,Alexandra Leary,Gabe S. Sonke,Charlie Gourley,Susana Banerjee,Amit M. Oza,Antonio González-Martín,Carol Aghajanian,William H. Bradley,Cara Mathews,Joyce F. Liu,Elizabeth S. Lowe,Ralph Bloomfield,Paul DiSilvestro +20 more
TL;DR: The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression‐free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olAParib than with placebo.
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
TL;DR: There was a statistically significant positive correlation between percent maximal cytoreduction and log median survival time, and this correlation remained significant after controlling for all other variables.
2.1K
A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J. Perren,Ann Marie Swart,Jacobus Pfisterer,Jonathan A. Ledermann,Eric Pujade-Lauraine,Gunnar B. Kristensen,Mark S. Carey,Philip Beale,Andrés Cervantes,Christian Kurzeder,Andreas du Bois,Jalid Sehouli,Rainer Kimmig,A. Stähle,Fiona Collinson,Sharadah Essapen,Charlie Gourley,Alain Lortholary,Frédéric Selle,Mansoor Raza Mirza,Arto Leminen,Marie Plante,Dan Stark,Wendi Qian,Wendi Qian,Mahesh K. B. Parmar,Amit M. Oza,Icon investigators +27 more
TL;DR: In patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months, higher than the average for women with ovarian cancer.